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Hepatocellular Carcinoma (HCC) is especially prevalent in parts of Asia and 
Africa. About 80% of people with hepatocellular carcinomas have cirrhosis. Chronic 
infection with the hepatitis B virus and hepatitis C virus also increases the risk of 
developing hepatocellular carcinoma. HCC is a difficult cancer to diagnose and thus 
treatment is usually administered too late.  
 A previous microarray study done revealed 218 genes with potential to be 
diagnostic markers due to significant differential expression in tumour relative to non-
tumor tissues. Corticotrophin-releasing hormone binding protein (CRH-BP) was one of 
these genes. It is a secreted protein that is associated with regulation of CRH. CRH-BP 
expression was down-regulated in HCC derived cell lines and clinical samples as 
measured by quantitative real-time PCR and regular RT-PCR. To explore the possible 
reason behind this down-regulation, MSP and 5-Aza-dC treatment was carried out. 
These two procedures confirmed that CpG island hypermethylation was the cause of 
the gene silencing in HCC. Over-expression of CRH-BP in HCC cell lines did not 
affect cell proliferation in liquid culture and anchorage- independent growth in soft 
agar. We thus successfully demonstrated that CRH-BP was a gene silenced in HCC due 
to CpG island hypermethylation and may have potential to be a diagnostic marker for 
HCC.  
 




















Epigenetic abnormalities affect the expression of several genes and are one of 
the most frequently occurring mechanisms of transcriptional silencing of tumour-
suppressor genes in cancers (Domann et al., 2000).   Aberrant CpG methylation has 
been found to occur in many genes involved in numerous functional groups and 
pathways leading to malignancy (Baylin et al., 2001). This phenomenon has resulted 
in the down regulation of these genes in human carcinogenesis.  
 
1.1 Hepatocellular Carcinoma 
Hepatocellular Carcinoma (HCC) is a frequently occurring worldwide 
malignancy with a high and aggressive rate of metastasis. It is the fifth most common 
neoplasm in the world, and the third most common cause of death with a significant 
geographic bias to Far East Asia and Africa (Parvez et al., 2004 and Srivantanakul, et 
al., 2004). Chronic hepatitis B and C virus infection, environmental carcinogens such 
as alfatoxin B1 (AFB1) exposure, alcoholic cirrhosis and inherited genetic disorders 
such as hemochromatosis, Wilson disease, α1–antitrypsin deficiency and tyrosinemia 
are considered major etiological factors associated with the development of HCC 
particularly as a result of their induction of chronic inflammation (Budhu et al., 
2006). Among them, HBV, HCV and AFB1 are responsible for 80% of all HCCs 
(Bosch et al., 1999). Although hepatocarcinogenesis is a multi-step process, the 
molecular changes that underpin histopathological changes in tumour development 
Chapter 1 Introduction 
 
 -3- 
are likely to be different in individual tumours. Figure 1 summerises the current 






Figure 1 Summary of multi-stage hepatocarcinogenesis associated with different 
risk factors.  (CMAR, cellular adhesion regulatory molecule). (Modified from Staib 
et al. TP53 and liver carcinogenesis. Human Mutation, 21:201-216,2003. Copyright 
© 2003 by Wiley-Liss, Inc.) 
 
 
The development of HCC is not a random event. Though such environmental 
risk factors as mentioned above have been clearly defined, the understanding of the 
molecular pathways of hepatocarcinogenesis is still limited. The extensive 
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heterogeneity of genomic lesions displayed by HCCs suggests that HCC may be 
produced by selection of both genomic and epigenetic alterations that comprise more 
than one regulatory pathway (Thorgeirsson et al., 2002). Therefore, a clear definition 
of the genetic and epigenetic aberrations that characterise hepatocarcinogenesis 
would be of value. Although both genetic alterations (e.g. chromosomal deletions, 
amplifications, and point mutations) and epigenetic alterations (regional CpG island 
hypermethylation and overall hypomethylation) play significant roles in 
hepatocarcinogenesis, the associations between these two carcinogenesis pathways 
are far from clear (Katoh et al., 2006). Difficulties in early diagnosis, treatment and 
its rapidly advancing nature, make HCC a very challenging malignancy to contain.  
 
1.2 Epigenetics 
Epigenetics refers to the study of the heritable changes in gene expression that 
occur without a change in DNA sequence (Rodenhiser et al., 2006). Epigenetic 
mechanisms provide an “extra” layer of transcriptional control that regulates how 
genes are expressed. It includes the study of effects that are inherited from one cell 
generation to the next whether these occur in embryonic morphogenesis, 
regeneration, normal turnover of cells, tumours, cell culture, or the replication of 
single celled organisms. Recently, there has been increasing interest in the hypothesis 
that some forms of epigenetic inheritance may be maintained even through the 
production of germ cells (meiosis), and therefore may endure from one generation to 
the next in multicellular organisms (Waterland et al., 2003). There are two primary 
and interconnected epigenetic mechanisms - DNA methylation and covalent 
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modification of chromatin. In addition, it is also becoming apparent that RNA is 
intimately involved in the formation of a repressive chromatin state. 
 
Chromatin is the complex of proteins (histones) and DNA that is tightly 
bundled to fit into the nucleus. The complex can be covalently modified by processes 
such as acetylation, ubiquitylation, phosphorylation,  and sumoylation of the amino 
acids that make up these histone proteins. Enzymes and some forms of RNA such as 
microRNAs and small interfering RNAs can also play important roles in modifying 
these histones. This modification alters chromatin structure to influence gene 
expression. In general, tightly folded chromatin tends to be shut down, or not 
expressed, while more open chromatin is functional, or expressed. Since DNA is not 
completely stripped of nucleosomes during replication, the remaining modified 
histones are thought to template identical modification of surrounding new histones 
after deposition. It should be noted, though, that not all histone modifications are 
inherited from one generation to another. The unstructured termini of histones (called 
histone tails) are particularly highly modified (Waterland et al., 2003).  
 
For example, acetylation of the K14 and K9 lysines of the tail of histone H3 
by histone acetyltransferase enzymes (HATs) is generally correlated with 
transcriptional competence. It is known that since lysine normally has a positive 
charge on the nitrogen at its end, it can bind the negatively charged phosphates of the 
DNA backbone and prevent them from repelling each other. When the charge is 
neutralized, the DNA can fold tightly, thus preventing access to the DNA by the 
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transcriptional machinery. When an acetyl group is added to the +NH2 of the lysine, 
it removes the positive charge and causes the DNA to repel itself and not fold up so 
tightly. When this occurs, complexes like SWI/SNF and other transcriptional factors 
can bind to the DNA, thus opening it up and exposing it to enzymes like RNA 
polymerase so transcription of the gene can occur.  
 
On the other hand, many scientists believe that lysine acetylation acts as a 
beacon to recruit other activating chromatin modifying enzymes (and basal 
transcription machinery as well). Indeed, the bromodomain—a protein segment 
(domain) that specifically binds acetyl-lysine—is found in many enzymes that help 
activate transcription including the SWI/SNF complex (on the protein polybromo). It 
may be that acetylation acts in this and the previous way to aid in transcriptional 
activation (Li H.P. et al., 2005). 
 
Currently, DNA methylation patterns are the longest-studied and best-
understood epigenetic markers. This involves the addition or removal of a methyl 
group (CH3), predominantly where cytosine bases occur consecutively. 
 
1.3 DNA Methylation 
DNA methylation in humans occurs almost exclusively at CpG dinucleotides 
and most CpG sequences in the genome are methylated (Egger et al., 2004). More 
than 50% of human genes are associated with CpG islands. The mammalian DNA 
methylation machinery is made up of two components, the DNA methyltransferases 
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(DNMTs) that establish and maintain DNA methylation patterns genome-wide, and 
the methyl-CpG binding proteins (MBDs), which are involved in ‘reading’ the 
methylation mark. DNA methylation is a potent mechanism for silencing gene 
expression and maintaining genome stability in the face of a vast amount of repetitive 
DNA. CpG islands, particularly those associated with gene promoters, are generally 
unmethylated, although an increasing number of exceptions are being identified 
(Bird, 1986; Song et al., 2005).   
Little is known about how DNA methylation is targeted to specific regions, 
however it most likely involves interactions between the DNMTs and chromatin-




















Figure 2. Chromatin regions and methylation. Transcriptionally active chromatin 
regions tend to be hyperacetylated and hypomethylated.  If a region of DNA or a gene 
is destined for silencing, chromatin remodeling enzymes such as histone deacetylases 
and ATP-dependent chromatin remodelers likely begin the gene silencing process.  
One or more of these activities may recruit DNA methyltransferase resulting in DNA 
methylation, followed finally by recruitment of the methyl-CpG binding proteins.  
The region of DNA will then be heritably maintained in an inactive state. 
 
 
Methylation involves the addition of a methyl group at the fifth carbon of the 
pyrimidine ring (in the same position as in thymine) of the CpG dinucleotide as 
shown in figure 3. Three DNMT genes (DNMT1, DNMT3a and DNMT3b) are 
responsible for the enzymatic addition of the methyl group, with S-adenosyl 
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methionine as the methyl donor (Zhu, 2006). There are in total five known DNMT 
family members- DNMT1, 2, 3A, 3B, and 3L as represented in figure 4. DNMT1 is 
the most abundant and catalytically active enzyme in most cell types, which 
associates with S-phase replication foci (Leonhardt et al., 1992; Chuang et al., 1997; 
Yokochi et al., 2002).  Its primary role is believed to be that of a maintenance 
methyltransferase (Bestor et al., 1996; Bestor, 2000), copying DNA methylation 
patterns following DNA replication.  Murine knockouts of Dnmt1 are embryonic 
lethal at day E8.5.   
 
The function of DNMT2 remains unclear since it possesses very low 
enzymatic activity in vitro and knockout of the gene in mice produces no discernable 
phenotype (Okano et al., 1998; Yoder et al., 1998; Hermann et al., 2003).  DNMT3A 
and DNMT3B are regarded as de novo methyltransferases since they are highly 
expressed at the stage of murine embryonic development (embryo implantation) when 
waves of de novo methylation are occurring in the genome (Okano et al., 1999). 
Murine Dnmt3a knockout mice are born live but die before reaching four weeks of 
age.  Dnmt3b knockout mice are embryonic lethal by day E14.5.  Dnmt3a knockout 
mice exhibit subtle DNA methylation defects in maternally imprinted regions (Hata et 
al., 2002), while Dnmt3b knockout mice show marked demethylation of 
pericentromeric satellite repeats (Okano et al., 1999).  Interestingly, knockout of 
Dnmt3L, which is not a functional enzyme due to lack of critical catalytic site motifs, 
results in maternal DNA methylation imprint failure and male sterility in mice (Hata 
et al., 2002). 









Figure 4. DNA methyltransferases. There are currently five members of the 
DNA methyltransferase family in mammalian cells.  All of these proteins have 
their catalytic domain in the C-terminal region, and (with the exception of 
DNMT2) a regulatory domain in the N-terminal region.  The N-terminal region 




Figure 3. Cytosine (CpG) methylation. DNA 
methyltransferases 1, 3A, or 3B catalyses the addition 
of a methyl group (the circled CH3) at the fifth carbon 
of the pyrimidine ring of the cytosine nucleotide by 
using the S-adenosyl methionine (SAM-CH3) as a 
methyl donor. 
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Methyl group tags in the DNA of humans and other mammals play an 
important role in determining whether some genes are or are not expressed. Genes 
unnecessary for any given cell's function can be tagged with the methyl groups. The 
number and placement of the methyl tags provides a signal saying that the gene 
should not be expressed. There are proteins in the cell, which specifically recognize 
and bind the tagged C's, preventing expression of the gene. Abnormal DNA 
methylation plays an important role in other developmental diseases as well and it 
especially develops with aging. 
 
Among all the epigenetics research conducted so far, the most extensively 
studied disease is cancer and the evidence linking DNA methylation to malignancies 
is very compelling.  
  
1.4 DNA methylation and cancer 
Cancer is a systemic disease, attributable to multiple lesions, either genetic or 
epigenetic, which have accumulated throughout a “lengthy” carcinogeneic process 
(Zhu, 2006). It was recognized nearly twenty years ago that DNA methylation 
patterns in tumour cells are altered relative to those of normal cells (Goelz et al., 
1985; Feinberg et al., 2004).  Tumour cells exhibit global hypomethylation of the 
genome accompanied by region-specific hypermethylation events (Baylin et al., 
2001).  Most of the hypomethylation occurs in repetitive DNA that is normally 
heavily methylated (Yoder et al., 1997).  This results in increased transcription from 
transposable elements and an elevated mutation rate due to mitotic recombination 
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(Chen et al., 1998; Eden et al., 2003).  Regions that are frequent targets of 
hypermethylation events are CpG islands. Figure 5 shows how abnormal methylation 
of CpG islands can efficiently repress transcription of the associated gene in a manner 
akin to deletion. There are now numerous lines of evidence indicating that aberrant 




Figure 5. How is DNA methylation targeted in normal cells & what goes wrong 
in cancer?  In normal cells (top) DNA methylation is concentrated in repetitive 
regions of the genome and most CpG island promoters are unmethylated.  In tumour 
cells, the compartmentalization breaks down and repetitive DNA loses methylation 
while CpG island promoters acquire it, resulting in silencing of the associated gene.  
The DNMTs are likely targeted to particular regions via protein-protein interactions 
within chromatin.  
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The demonstration of a strong relationship between aberrant CpG methylation 
in specific transcriptional regulatory elements and the absence of expression, together 
with increasingly amenable and robust analytical techniques, have encouraged 
numerous studies of methylation silencing. A large number of genes have now been 
reported to be methylated in a wide variety of cancers. Genes silenced in cancer 
comes from all known functional classes involved in various pathways of cancer 
development. Table 1 shows a small selection of these genes. 
Gene Cancer(s) Proposed effect Ref. 
14-3-3σ Breast, head, neck and 
liver 
Loss of G2 checkpoint Ferguson, 2000 
Gasco, 2002 
ASPP1 Breast, lymphoma Loss of pro-apoptotic p53 signaling Agirre, 2006 




CHFR Lung, oesophagus, 
stomach 
Loss of mitotic checkpoint. Increased 
taxane sensitivity 
Scolnick, 2000 
TP73 Lymphoma Loss of p73-dependent apoptosis. 
Chemoresistance 
Corn, 1999 
FANCF Ovary Sensitivity to cross-linking agents Taniguchi, 2003 
BRCA1 Ovary Sensitivity to cross-linking agents Teodoridis, 2005 
APAF1 Malignant melanoma Failure of p53-dependent apoptosis. 
Resistance to cytotoxic drugs 
Soengas 2001 
HMLH1 Ovary Resistance to cisplatin and alkylating 
agents 
Gifford, 2004 
MGMT Ovary, glioma, 
lymphoma 
Sensitivity to alkylating agents Teodoridis, 2005 
Esteller, 2000, 2002 
ERβ Breast Tamoxifen sensitivity Chang, 2005 
Maspin Breast Metastasis Domann, 2000 
E-cadherin Breast, thyroid, gastric Metastasis Graff, 1998, 2000 
Reelin Pancreas Metastasis Sato, 2006 
DAB1 Pancreas Metastasis Sato, 2006 
 
Table 1.Genes methylated in cancer cells that may have important clinical 
effects. The list is by no means exhaustive. APAF1: Apoptotic peptidase activating 
factor 1; ASPP1: Apoptosis-stimulating protein of p53, 1; BRCA1: Breast cancer 1, 
early onset; CHFR: Checkpoint with forkhead and ring finger domains; DAB1: 
Disabled homolog 1; ERβ: Estrogen receptor β; FANCF: Fanconi anemia, 
complementation group F; hMLH1: MutL homolog 1, colon cancer, nonpolyposis 
type 2; SNK/PLK2: Serum inducible kinase/polo-like kinase 2; TP73: Tumour 
protein p73. 




A brief list of the most significant genes inactivated by DNA methylation is 
represented in Table 1. Most of these genes that have been proven to be methylated in 
tumour cells but not in normal cells are usually part of the cell cycle like p16INK4b 
(Herman et al., 1996) the p53 network like p14ARF (Esteller et al., 2001) or the 
APC/β-catenin/E-cadherin pathway like E- and H-cadherin (Toyooka et al., 2001). 
Other well-studied pathways affected by DNA methylation include DNA repair, 
hormonal response and cytokine signalling. Thus, ample evidence exists to support 
the notion that DNA hypermethylation acts as a primary inactivating event 
contributing directly to tumourgenesis. 
 
Currently, one cannot conclude why some genes become hypermethylated in 
certain tumours, whereas others with similar properties (a typical CpG island, a 
history of loss of expression in certain tumours and the absence of mutations) remain 
methylation-free. We can hypothesise, as researchers have done before with genetic 
mutations, that a particular gene is preferentially methylated with respect to others in 
certain tumour types because inactivation confers a selective advantage, in the 
Darwanian sense, on the former. Another option is that aberrant DNA methylation is 
directly targeted. Selection and targeting are not exclusive events and they are 
probably happening together in the generation and maintenance of hypermethylated 
CpG islands of tumour suppressor genes (Esteller, 2005).  
 
 




1.5 DNA methylation and HCC 
Difficulties in the early diagnosis and clinical management of HCC, such as 
inherent and adaptive resistance to the common chemotherapeutic modalities, and its 
rapidly advancing nature, have made HCC one of the most challenging malignancies 
to contain. In this connection, the staging and classification system for this 
malignancy based upon clinical observations, imaging, and biochemical data, remains 
rather empirical and inadequate (Zhu, 2006). Recent appreciation of the involvement 
of epigenetic abnormalities in cancer formation, DNA methylation in particular, has 
brought about intensified efforts to establish HCC-specific pattern of DNA 
methylation. 
 
In HCCs, a growing number of genes have been recognised as undergoing 
aberrant CpG island hypermethylation, which is associated with the transcriptional 
inactivation and loss of gene function, suggesting that CpG island hypermethylation 
is an important mechanism for the development of HCC. Most studies have focussed 
on single target genes (Kanai et al., 1997; Liew et al., 1999; Iwata et al., 2000; Tchou 
et al., 2000 and Kaneto et al., 2001) and a few have attempted to analyse the 
hypermethylation of multiple genes in HCCs and associated chronic liver diseases 
(Kondo et al., 2000; Saito, 2001 and Shen et al., 2002). Pathologically defined 
neighbouring non-cancerous tissues likely represent an entity at the pre-malignant 
stage of carcinogenesis, characterised with a unique pattern of both genetic and 
epigenetic defects (Figure 6A). The assumption is probably correct that targets 
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exhibiting a significantly higher frequency of changes in DNA methylation in tumour 
tissues than in the neighbouring tissues represent a late phase of carcinogenesis with 
early-phase-specific changes occurring at the same frequency in both types of tissues 
(Figure 6B and C). Evaluation of the advantages of some of these late-phase genes as 
therapeutic targets for genetic intervention, by reactivating their expression or 













Figure 6. Phase-specific alterations in the methylation of promoter CpG islands 
in genes in hepatocellular carcinoma.  
A Schematic presentation of the concepts of phase-specific methylation during 
carcinogenesis of liver cancer. B Genes with earlyphase changes display similar 
frequencies of changes in both cancerous and neighbouring noncancerous tissues, 
while C the genes involved in late-phase changes show a significantly higher rate of 
change in cancer than in the neighbouring noncancerous tissues. Both χ2 and P values 
for each gene were calculated, and are shown in the tables. The genes shown in bold 
italics exhibit decreased methylation in cancer. C, cancer tissue; N, neighbouring non-
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1.6 CRH-BP and CRH 
Corticotrophin-releasing hormone binding protein (CRH-BP) is a 37-kD 
plasma protein of 322 amino acids, containing one putative N-glycosylation site, 10 
cysteines and five tandem disulfide bridges, which are all essential for its action 
(Petraglia et al., 1996). The integrity of the disulfide bonds is fundamental for its 
binding activity, as reduction abolishes the protein’s ability to bind CRH (Zhao et al., 
1997). Mapped to the distal region of chromosome 5q11.2 – q13.3, CRH-BP is the 
only example of a neuropeptide-binding protein discovered this far. The promoter 
sequence was found to contain promoter elements including two liver-specific 
enhancers (LFA1, LAB1), immunoglobulin enhancer elements (NFκB), interferon-1, 
a transcription factor known to regulate the interferon gene, and estrogen receptor 
half-sites (Behan et al., 1993). 
 
The ability of glucocorticoids and exogenous CRH to lower plasma CRH-BP 
levels and of CRH-BP to modulate the bioactivity of circulating CRH suggest that the 
protein may be an important regulator of circulating CRH and related ligands (Trainer 
et al., 1998). Its core function is thus to sequester the action of CRH and its 
downstream events through neutralising the ACTH-releasing activity of human CRH. 
It is expressed mainly in the liver (Potter et al., 1991), placenta (Petraglia et al., 1993) 
and brain (Potter et al., 1992). Of the species examined this far (sheep, cow, rat, 
mouse), only humans and perhaps some other higher primates express CRH-BP in the 
liver; however all of these species express CRH-BP in the brain (Vale et al., 1997). 
CRH-BP is a secreted protein and can be easily detected in biological fluids like the 
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blood where it appears to be present in great excess in comparison to the virtually 
undetectable amounts of plasma CRH found in basal conditions. 
 
Maternal plasma CRH-BP levels in healthy pregnant women rise significantly 
at 30-35 weeks of pregnancy and fall dramatically at 38-40 weeks (Petraglia et al., 
1996). It is a known fact that intrauterine tissues produce CRH and this is released 
into the maternal circulation, thus contributing to the plasma CRH levels which 
increase progressively throughout gestation. Thus, the capacity of CRH-BP to bind 
CRH and the presence of circulating CRH-BP plasma levels during pregnancy may 
explain why the high maternal plasma CRH during the third trimester of pregnancy 
does not increase plasma ACTH and cause hypercorticolism (Suda et al., 1984).  
CRH-BP has also proven to block the activity of CRH on human pregnant 
endometrium prostaglandin release and on human myometrium contractibility in vitro 
(Petraglia, 1996). In these ways and more, CRH-BP plays an important role in 
controlling the cascade of events that are critical for parturition. 
 
CRH-BP has also been proven to play a role in the hypothalamo-pituitary-
adrenal  (HPA) axis (Trainer et al., 1998). It has been speculated that the low levels 
of CRH in the cerebrospinal fluid of patients with Alzheimer’s disease, due to the 
increased levels of CRH-BP, may contribute to their cognitive impairment, a situation 
potentially exacerbated by the normal levels of CRH-BP and, by implication, even 
lower levels of free CRH. Displacement of CRH from its binding protein has been 
suggested as a possible treatment for Alzheimer’s disease (Behan et al., 1993). 
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CRH-BP has been known to take part in immune/inflammatory reactions as an 
auto/paracrine proinflammatory regulator as well as in some pathological conditions 
(Zhao et al., 1997).  
 
Corticotrophin-releasing hormone (CRH) is a 41 amino acid polypeptide that 
functions as the primary neuroendocrine integrator of the vertebrate stress response 
(Valverde et al., 2001). It is released following emotional or physical stress and 
initiates a cascade of endocrine signalling events by regulating the release of 
adrenocorticotropin (ACTH), β-endorphin, and other proopiomelanocortin (POMC)- 
derived peptides from the pituitary (Zhao et al., 1997; Valverde, 2001). There is an 
overall elevation in plasma glucocorticoids. It is known to influence appetite, 
locomotion, and behavioural responses to stress and anxiety (Glowa et al., 1992; 
Linthorst et al., 1997). It is essential for adaptive developmental responses to 
environmental stress. For example, CRH-dependent mechanisms cause accelerated 
metamorphosis in response to pond drying in some amphibian species, and 
intrauterine fetal stress syndromes in humans precipitate preterm birth (Denver, 
1999). It may be a phelogenetically ancient developmental signalling molecule that 
allows developing organisms to escape deleterious changes in their larval/fetal 
habitat. On top of its hypophysiotropic role, CRH also controls appetite, behavioural 
responses to stress (arousal, escape), and modulation of immune responses, among 
others (Vale et al., 1997).  
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Higher expression of CRH has been detected in thyroid carcinomas (Scopa et 
al., 1994) and breast cancers (Ciocca et al., 1990). The reduced expression of CRH-
BP in HCC and other tumour cells could help explain this phenomenon.  
 
1.7 The objectives of this study 
Transcriptional silencing resulting from changes in epigenetic regulation of 
gene expression is the most frequent mechanism by which tumour suppressor genes 
are inactivated in human cancer. Methylation profiling can identify distinct subtypes 
of common human cancers and may have utility in predicting clinical phenotypes in 
individual patients. Epigenetic analysis is likely to have an increasingly important 
part to play in the diagnosis, prognostic assessment and treatment of malignant 
disease.   
 
The two main objectives of this project are (1) to further examine the possible 
mechanism of CRH-BP and its functional role in hepatocarcinogenesis, and (2) to 
evaluate the role of DNA methylation in modulating CRH-BP expression. 
 
The main goal of this project is to increase the understanding of CRH-BP in 
HCC. There is no evidence of any previous studies done on the protein’s possible role 
in cancer. In a previous study, the CRH-BP expression has been found to be down-
regulated in HCC by comparing 37 pairs of matched HCC tumour and non-tumour 
liver samples using cDNA microarrays analysis (Neo et al., 2004). In this present 
study, we confirmed that the expression of CRH-BP was down regulated in HCC 
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tumour tissues and in all 14 HCC cell lines tested. This makes CRH-BP an interesting 
protein to study.  
 
Among the approaches used to assess the methylation state of CRH-BP DNA, 
methylation- specific polymerase chain reaction (PCR) method (MSP) and 5-aza-dC 
treatment were selected. These methods have wide appeal, as they are sensitive and 
specific.  


















2 MATERIALS AND METHODS 
General laboratory chemicals were of analytical grade and were obtained from 
Sigma (USA) or MERCK (USA) unless otherwise specified. 
 
2.1 CELL CULTURE TECHNIQUES 
2.1.1 Maintenance of cell lines 
Eleven human hepatocellular cancer (HCC) cell lines HA22T, Hep3B, Huh1, 
Huh4, PP5, Tong, Huh6, Huh7, HepG2, Mahlavu and SKHep-1 were maintained in 
Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% Fetal Bovine 
Serum and 2mM glutamine, at 37°C in a humidified atmosphere of 5% CO2.  The 
other three HCC cell lines, SNU182, SNU449 and SNU475 were cultured in RPMI 
supplemented with 10% Fetal Bovine Serum and 2mM glutamine, at 37°C in a 
humidified atmosphere of 5% CO2. Cells were fed every 3 days or split whenever 
they grew too dense. 
All the reagents and media used in cell culture were purchased from 
Invitrogen (Carlsbad, CA). 
 
2.1.2 Transfection 
One day before transfection, 0.5-2 x 105 cells were plated into each well of a 
6-well plate with 2 ml of growth medium without antibiotics so the cells will be at 
95% confluency at the time of transfection. Cells are transfected at high cell density 
for high efficiency, high expression levels, and to minimize cytotoxicity.  
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To transfect the CRH-BP DNA insert into mammalian cells, HepG2 and 
Hep3B, a 6-well plate was used. Complexes were prepared using a DNA (µg) to 
Lipofectamine™ 2000 (µl) ratio of 1:3. For each sample, DNA was diluted in 50 µl 
of DMEM without serum. Lipofectamine™ 2000 was then diluted in 50 µl of 
DMEM. After a 5 min incubation at room temperature, the diluted DNA was 
combined with the diluted DNA with diluted Lipofectamine™ 2000. This was left to 
incubate for 20 min at room temperature and then added to the plated well. The cells 
were left to incubate at 37°C in a CO2 incubator for 24 hours prior to testing for 
transgene expression. Medium was changed 6 hours after transfection. Transfection 
efficiency was monitored for both HepG2 and Hep3B cell lines.  
 
2.1.3 5-Aza-dC treatment 
Stock solution of 10mmol/L of 5-Aza-dC (Sigma, St Louis, MO, USA), a 
demethylating agent, was prepared by dissolving it in DMSO and stored at -20°C. 3 x 
105 to 4 x 105 cells depending on the cell lines were seeded into 6-well plates and 
cultured for 24h before treatment with 5-Aza-dC. HCC cells were then treated with 
various concentrations, 0, 5 and 10 µM of 5-Aza-dC for 4 days. Total RNA was 
extracted from the cells at 72 h, 96 h and 120 h time points for RT-PCR assays. 
Media was changed every 48 h to ensure concentration of drug was maintained for 5-
Aza-dC is easily degraded. The experiments were repeated two times with consistent 
results obtained.  
 
 




2.2 TISSUE SAMPLES 
Total RNA of eight pairs of matched tumour and non-tumour liver tissues were 
randomly selected from previously collected RNA samples obtained from 37 HCC 
patients (Neo et al., 2004), and RNA samples from 15 types of normal human tissues 
were purchased from Stratagene (La Jolla, CA, USA). Genomic DNA of six pairs of 
matched tumour and non-tumour liver tissues were kindly provided by Neo Seok 
Ying from GIS, Singapore.   
 
2.3 IN SILICO WORK  
2.3.1 Determine site of CpG island in CRH-BP gene 
MethPrimer a programme used for designing bisulfite-conversion based 
methylation PCR primers at http://www.urogene.org/methprimer/index1.html was 
used for methylation mapping. DNA sequence of CRH-BP together with the promoter 
region, obtained from ensembl (www.ensembl.org) was inserted into the programme 
and the potential CpG islands were picked out. These regions had a GC content of 
greater than 60%.  
 
2.3.2 Design primers 
All oligonucleotides were synthesised by First Base, Singapore. The position 
of the oligonucleotides corresponds to the exons of the genes and usually has an 
intron within it.  
Two types of primers were designed. Primer3 (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) was used to design primers for the regular PCR 
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whereas MethPrimer was used to design primers for Methylation specific PCR 





CRH-BP-MF 5' ACGGTTTTAAGAGGGGAAAGTC 3' 128 
CRH-BP-MR 5' ACGAACCCCAAAAAACTACG 3'  
   
CRH-BP-UF 5' GATGGTTTTAAGAGGGGAAAGTT 3' 128 
CRH-BP-UR 5' AACAAACCCCAAAAAACTACA 3'  
   
CRH-BP-f 5’ CCAGCATGTCGCCCAACTT 3’ 700 
CRH-BP-r 5’ CCTATTCCCTCGCAACCTG 3’  
   
GAPDH-f 5’ ACCACAGTCCATGCCATCA 3’ 453 
GAPDH-r 5’ TCCACCACCCTGTTGCTGTA 3’  
   
HPRT1-f 5’ ATGACCAGTCAACAGGGGAC 3’ 192 
HPRT1-r 5’ CCAGCAAGCTTGCGACCTTGACCA 3’  
   
GW-CRH-BP-f 5’ AAA AAG CAG GCT CCA GCA TGT CGC 
CCA ACT TC 3’ 
- 
GW-CRH-BP-r 5’ AGA AAG CTG GGT AAA GAC CAG ACA 
AAC AGA ATT C 3’ 
- 
 
Table 2. Oligonucleotide primers and probes used in RT-PCR and real-time PCR. 




2.4 RNA WORK 
 
2.4.1 RNA extraction 
 
RNA from transfected and treated HCC cells was extracted using the RNeasy 
Mini Kit (Qiagen, Valencia. CA) according to the centrifugation protocol as 
described by the manufacturer.  
The cells were first washed with Phosphate Buffered Saline (PBS) twice and 
then 350 µl of RLT with β-ME was added to each well of a 6-well plate. This was 
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than transferred into an eppendorf tube and vortexed to homogenise the mixture. 350 
µl of 70% ethanol was then added. After thorough mixing by pipetting, the solution 
was transferred to an RNeasy spin column. After centrifuging for 15 s at 8000 x g, the 
flow-through was discarded. 700 µl of RW1 and 500 µl of RPE was added 
consecutively to wash the spin column membrane. Each step was followed by 15 s of 
centrifuging at 8000 x g. 500 µl of RPE was added for the final wash and centrifuged 
at maximum speed for 2 min. 30 µl of RNase-free water was then added to elude the 
RNA and centrifuged at 10,000 x g for 1 min. The RNA was then incubated at 70°C 
for 10 min followed by at 4°C for 5 min to denature the secondary structure of RNA. 
This was stored at -20°C. 
 
2.4.2 RNA quantitation 
 
The NanoDrop® ND-1000 Spectrophotometer used only 1 µl of sample to 
quantify the amount of RNA by measuring the absorbance at 260 nm (A260).  
 
2.4.3 cDNA synthesis 
 
cDNA synthesis of the samples was done using an Omniscript© Reverse 
Transcriptase kit (Qiagen, Valencia. CA) according to the manufacturer’s 
instructions.  
For each 1 µg of total RNA, 2 µl of 10x Buffer RT, dNTP mix (5mM each 
dNTP), 0.5 µl of each forward and reverse primer, 1 µl of RNase inhibitor (10units/ 
µl) and 1 µl of Omniscript reverse transcriptase were added. RNase free water was 
then added to make the volume 20 µl. After centrifuging briefly, this mixture was 
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then left to incubate at 37°C for 1 h. A 10 x dilution was then done before 0.5-2 µl of 
it was used as a template for PCR.  
 
2.4.4 Reverse transcription polymerase chain reaction (RT-PCR) 
RT-PCR was performed with the products of the cDNA synthesis. 0.5 µl of 
synthesized cDNA was then amplified by PCR using the Taq PCR master mix (Roche 
Applied Science, Mannheim, Germany) and the primers found in Table 2. After an 
initial denaturation of 95°C for 2 min, PCR was performed in a 20 µl reaction volume 
for 38 cycles under the following conditions: 95°C for 30 s, 56°C for 45 s, 72°C for 
60 s, and finally an extension at 72°C for 10 min.15 µl of the PCR product was then 
run on a 1.5% agarose gel and visualized by Ethidium Bromide staining. 
 
 
2.4.5 Real-time polymerase chain reaction 
 
RNA expression of CRH-BP in eight pairs of liver tissues was analyzed by 
real-time quantitative RT-PCR using LightCycler RNA Master SYBR Green I kit 
(Roche Applied Science, Mannheim, Germany) using previously collected total RNA 
samples (Neo et al., 2004). Data is represented as the fold change of CRH-BP 
expression in each non-tumour tissue relative to its corresponding tumour sample 
after normalized to housekeeping gene HPRT. The primers used are listed in Table 2. 
 
 
2.4.6 DNA electrophoresis 
 
PCR products were analysed by agarose gel electrophoresis. DNA fragments 
mixed with DNA loading buffer (0.2% w/v) each of bromophenol blue and xylene 
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cyanol in 30% (w/v) glycerol were separated on a 1.5% agarose gel containing 1 µg/ 
ml ethidium bromide in 1X TAE electrophoresis buffer (40mM Tris-acetate and 1mM 
EDTA). GeneRuler™ 1kb and 100bp DNA ladder (Invitrogen, USA) were used to 
determine DNA fragment size. The separated DNA fragments were then visualised 
using a UV-transilluminator. 
 
2.4.7 Statistical Analysis 
 
The correlation between the decreased folds of CRH-BP mRNA expression in 
HCC tumour tissues tested by real-time PCR and cDNA microarray assay was 
established by calculating the Pearson’s correlation coefficient (r). P-value less than 
0.05 was considered statistically significant. 
 
2.5 DNA WORK 
 
2.5.1 Genomic DNA extraction 
 
Genomic DNA was extracted from each hepatoma cell line using a DNeasy 
Tissue Kit (Qiagen, Valencia, CA) according to centrifugation protocol as described 
by the manufacturer. 
A maximum of 5 x 108 cells were centrifuged for 5 min at 300 x g. The pellet 
was then resuspended in 200 µl of PBS. 20 µl of proteinase K was then added to get 
rid of all the proteins found in the pellets. 200 µl of Buffer AL was added and the 
mixture vortexed well to result in a homogeneous solution. 200 µl of 100% ethanol 
was added after and the mixture was transferred into a DNeasy Mini spin column. 
This was centrifuged for 1 min at 6000 x g and the flow through discarded. 500 µl of 
wash buffer AW1 was then added and the column centrifuged for 1 min at 6000 x g. 
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The column was then placed into a new 2 ml collection tube and 500 µl of wash 
buffer AW2 was added. After centrifuging for 3 min at 20,000 x g (14,000 rpm) to 
dry the DNeasy membrane, the column was then placed in a clean 1.5 ml or 2 ml 
microcentrifuge tube and 100 µl of sterile water was added and this was left to 
incubate for 1 min at room temperature before once again centrifuging for 1 min at 
6000 x g to elude. 
 
2.5.2 Methylation-specific Polymerase Chain reaction (MSP) 
 
  The genomic DNA was modified by sodium bisulphite using MethylEasy™ 
DNA Bisulphite modification kit (Human Genetic Signatures, Australia) according to 
the manufacturer’s instructions. On the first day, 1 µg of genomic DNA (gDNA) was 
diluted in 20 µl of water. 2.2 µl of 3M NaOH was added into each 20 µl reaction. This 
was left to incubate at 37°C for 15 min. 220 µl of a mixture of 10 mM hydroquinone 
reagent and 3M Sodium bisulfite was then added. This was gently mixed and 200 µl 
mineral oil added. The mixture was left to incubate at 55°C for 16 h.  
  The next day, all traces of mineral oil was removed and 2 µl of glycogen 
added followed by 800 µl of a reagent for DNA clean up. After vigorous pipetting, 1 
ml of isopropanol was slowly added by gently pipetting after each addition. This was 
left to incubate at 4°C for 30 min and the supernatant removed after 10 min of 
centrifuging at 15,000 x rpm at 4°C. After adding 500 µl of 70% ethanol and 
centrifuging for 5 min at 15,000 x rpm at 4°C, all traces of ethanol was removed and 
the pellet left to dry. The pellet was then resuspended in 20 µl of TE buffer and 
incubated at 72°C for 60 min. 1 µl of the final result was used as a template for each 
PCR reaction. 




For detection of aberrant methylation of CRH-BP, modified DNA was 
amplified using primers specific for the methylated sequences (Table 2). For quality 
control of the bisulphite modification process, the modified DNA was also amplified 
using primers listed in Table 2 specific for the unmethylated sequence of each gene. 1 
µl of treated DNA was amplified by PCR using the Taq PCR master mix (Roche 
Applied Science, Mannheim, Germany) in a 20 µl reaction volume for 45 cycles 
under these conditions: 95°C for 30 s, 56°C for 120 s, 72°C for 120 s, and finally an 
extension at 72°C for 10 min. 15 µl of the PCR product was then run on a 2% agarose 
gel and visualized by Ethidium Bromide staining. 
 
 
2.5.3 General Protocols for cloning 
 
2.5.3.1 Preparation of Competent Cells 
 
2.5.3.1.1 Competent cells for chemical transformation 
 
E.coli strains DH5α and BL21 (DE3) (Amersham Pharmacia Biotech, NJ, 
USA) were prepared for chemical transformation. DH5α cells were used for general 
cloning purpose, primarily for plasmid amplification.  
Stock cells were streaked onto LB plates and incubated overnight at 37°C. A 
single colony was grown in 25 ml of LB medium at 37°C overnight with vigorous 
shaking. 2.5 ml of the overnight culture was inoculated in 250 ml of SOB medium 
and the cells were grown at 18°C for 24-36 h with vigorous shaking until 
OD600=0.6. After keeping on ice for 10 min, the cells were harvested by centrifuging 
at 2,500 x g for 10 min at 4°C. The cells were resuspended gently in 80 ml of ice-cold 
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TB buffer (10mM Pipes, 55mM MnCl2 15mM Ca Cl2, 250mM KCl, pH6.7) and kept 
on ice for 10 min, then followed by centrifuging at 2,500 x g for 10 min at 4°C. The 
supernatant was poured off carefully and the cells were gently resuspended in 20 ml 
of ice-cold TB buffer, and DMSO was added to a final concentration of 7%. The cells 
were kept on ice for 10 min and aliquoted into tubes of 100 µl each and stored at -
80°C. 
 
2.5.3.2 Insert Preparation 
 
2.5.3.2.1 Insert from PCR product or sub-cloned fragment 
 
 The insert DNA was usually amplified from PCR reaction with specific 
primers and followed by gel purification for further restriction digestion. The PCR 
reaction was performed in a total volume of 50 µl under appropriate conditions, and 
all products were separated in 1-1.5% agarose gel. Viewed under UV 
transilluminator, the DNA fragment of expected size was cut out and purified using a 
QIAquick Gel Extraction Kit (Qiagen Gmbh, Hilden, Germany) according to 
manufacturer’s instructions. 15-20 µl of purified DNA was then digested with 
appropriate restriction enzymes. The reaction was carried out by 1.5-2 h incubation at 
37°C in a total volume of 100 µl, generally containing 2.5 µl of each enzyme for 
double digestion or 5 µl of enzyme for single digestion. All the digestion products 
were separated on 1-1.5% agarose gel and the digested insert DNA was purified again 
using the QIAquick kit. 
 In some situations, the target insert could be sub-cloned from a constructed 
plasmid. 10-15 µg of target plasmid was digested at 37°C for 1.5-2 h in a total 
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volume of 100 µl, in the presence of appropriate enzymes. The reaction products were 
separated on 1-1.5% agarose gel and the expected DNA fragment was purified using 
the QIAquick kit. 
 
2.5.3.2.2 End-fill-in reaction 
In certain circumstances, the sticky end(s) of the DNA fragment which 
resulted from the restriction digestion needed to be blunted by end-fill-in reaction in 
the presence of Klenow fragment of DNA-polymerase. In this case, 50 µl of digested 
DNA from gel purification was further incubated at 37°C for 30 min in a 100 µl 
reaction, containing 1x Ecopol buffer, 5 µl of 2.5 mM dNTPs, and 2 µl of Klenow 
enzyme (New England Biolabs, Beverly, MA). The blunt DNA was then extracted by 
gel purification and could be directly used for subsequent ligation or subjected to a 
second digestion to create one sticky end. 
 
2.5.4  Plasmid vector-pDEST40 and pDONR-221 
 
pcDNA-DEST40 is a 7.1 kb vector derived from pcDNA3.1/V5-His™ and 
adapted for use with the Gateway™ Technology (Invitrogen, USA). Figure 7 shows 
the map of pDEST40. Gateway™ is a universal cloning technology that takes 
advantage of the site-specific recombination properties of bacteriophage lambda 
(Landy, 1989) to provide a rapid and highly efficient way to move the gene of interest 
into multiple vector systems. 




Figure 7. Vector map of pcDNA-DEST40 from Invitrogen, USA. The map shows 
the main features of this vector and the various antibiotic resistances. T7 promoter is 
indicated as well. 
 
pDONR™221 is a bacterial vector used with the Gateway® Technology for 
easy cloning. It has a pUC origin for high plasmid yields and universal M13 




Figure 8. Vector map of pDONR™221 from Invitrogen, USA. The map shows the 
reading frames and main features of the vector.  
 




2.5.5 DNA Ligation 
The DNA of interest was first cloned into an easy clone vector before being 
cloned into the pDEST40 Vector system (Invitrogen, USA). The fragment of interest 
was ligated to the vector in a 10 µl reaction volume containing 1 µl of 5x ligation 
buffer (10mM Tris-HCL, pH 7.4, 50mM KCl, 1mM DTT, 0.1 mM EDTA and 50% 
glycerol, Promega, USA) and 1 µl of T4 DNA ligase (New England Biolabs). Molar 
ratio of insert-to-vector was 3:1. Ligation was performed at 24°C overnight. 
 
2.5.6 DNA transformation of E. coli cells 
The ligation reaction mix (10 µl) was added into 100 µl of E.coli DH5α 
competent cells and 40 µl of KCM (1M KCl, 1M CaCl2 and 1M MgCl2 dissolved in 
deionised water) and incubated on ice for 1h. The mixture was then plated out on a 
LB agar plate containing ampicillin and incubated overnight at 37°C to allow 
colonies of transformants to form. 
 
2.5.7 Bacterial culture 
Liquid columns of bacteria were grown in Luria-Bertani (LB) medium (10g of 
NaCl, 10g tryptone and 5g of yeast extract, adjusted to pH 7.0 with NaOH in 1L of 
deionised water). Agar plates were prepared by melting 1.5% bacto-agar (Difco, 
USA) in the LB medium. When necessary, ampicillin (Sigma, USA) was added to 
final concentration of 100 µg/ ml. 
 
 




2.5.8 Isolation and purification of plasmid DNA 
Small-scale preparation of plasmid DNA was carried out using the Wizard® 
Plus SV Miniprep Kit (Promega, USA) according to centrifugation protocol as 
described by the manufacturer. This protocol involved alkaline lysis, binding of 
plasmid to a spin column, followed by elution of DNA with water. 
8 ml of bacteria culture grown overnight in LB-ampicillin (50 µg/ µl) medium 
was harvested by centrifugation at 10,000 x g at -4°C for 10 min using the Eppendorf 
centrifuge, the bacterial pellet was resuspended in 250 µl of cell resuspension solution 
(50mM Tris-HCL, pH 7.5, 10mM EDTA, 100 µg/ ml RNase A), followed by 250 µl 
of cell lysis solution (0.2M NaOH, 1% SDS) and gently inverted 4 times to mix. 10 µl 
of alkaline protease (25 µg/ µl) was then added and incubated for 5 min at room 
temperature. Next, 350 µl of neutralization solution (4.09M guanidine hydrochloride, 
0.759M potassium acetate, 2.12M glacial acetic acid) was added followed by 4 times 
of gentle inversion. After centrifugation at 14,000 x g for 10 min, the clear lysate was 
transferred to a spin column in a collection tube and centrifuged for 1 min at 14,000 x 
g. The flow-through was discarded and the column was re-inserted into the collection 
tube. 750 µl of wash solution (60mM potassium acetate; 10mM Tris-HCl, pH 7.5; 
60% ethanol) was added to the spin column and centrifuged at 14,000 x g for 1 min. 
This step was repeated with 250 µl wash solution and centrifuged at 14,000 x g for 2 
min. The spin column was next transferred to a sterile 1.5 ml microcentrifuge tube 
and 30 µl of sterile water was applied, and left to stand for 1 min. Plasmid DNA was 
eluted by centrifugation at 14,000 x g for 1 min. 




2.6 PROTEIN WORK 
 
2.6.1 Lysate extraction and determination of protein extraction 
 
Cells were washed twice with PBS and then lysed in buffer (1% Nonidet P-40, 
150 mM NaCl, 50 mM Tris, pH 7.8) containing protease inhibitor mixture (Roche, 
USA) and 1 mM phenylmethylsulfonyl fluoride (Sigma) on ice for 30 min. The lysates 
were cleared by centrifuging at 13,000 rpm for 15 min at 4°C, and the protein 
concentration was measured using a BCA protein assay kit (Pierce, Rockford, IL). 
 
2.6.2  SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
Separating gels with 10% of acrylamide concentration were used in this study, 
while 5% of stacking gels was consistently applied, according to the protocols 
recommended by Sambrook et al (1989). Gels were cast using the mini-Protein II® 
electrophoresis cell apparatus (Bio-Rad) according to the manufacturer’s instructions. 
Formulations of SDS-polyacrylamide separating and stacking gels are listed in Table 
3. Receipes are sufficient for the preparation of 2 slab mini-gels (0.75mm thick and 
100 x 70 mm2) and the components were mixed in the order shown. Polymerisation 















Separating gels 10% 
  
H20 5.9 ml 
30% acrylamide mix (Bio-Rad) 5.0 ml 
1.5M Tris (pH8.8) 3.8 ml 
10% SDS 0.15 ml 
10% ammonium persulfate 0.15 ml 
TEMED (Sigma) 6 µl 
Total (for 2 gels)  15.0 ml 
  
Stacking gels 5% 
  
H20 4.1 ml 
30% acrylamide mix (Bio-Rad) 1.0 ml 
1.5M Tris (pH6.8) 0.75 ml 
10% SDS 60 µl 
10% ammonium persulfate 6 µl 
TEMED (Sigma) 6 µl 
Total (for 2 gels)  6.0 ml 
 
Table 3. Solutions for preparing SDS-PAGE 
 
 
2.6.3     Sample preparation and electrophoresis 
 
While the stacking gel was polymerising, the protein samles were prepared by 
heating them to 100°C for 5 min in 1 x SDS loading buffer, which contained 2% 
SDS, 1% β-mercaptoethanol, 50mM Tris-HCl (pH 6.8), 10% glycerol, and 0.3% 
bromophenol blue. 15-30 µl of each sample (10-30  µg) was separately loaded into 
the bottom of the sample wells. Electrophoresis was carried out for 1-1.5 h in the 
presence of 1 x Tris-glycine buffer (25 mM Tris, 250 mM glycine, pH 8.3, 0.1% 
SDS), with the current being constant at 20mM (one mini gel). Power supply was 
turned off when the dye front reached the bottom of the separating gel. Removed 
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carefully from the electrophoresis apparatus, the gel was used to establish Western 
blot. 
 
2.6.4 Western Blot Analysis 
 
To analyse the protein expression, various samples collected were separated in 
duplicate SDS-PAGE gels (10% polyacrylamide) according to the protocol described 
above. Pre-stained SDS-PAGE standards (Bio-Rad, Hercules, CA) were included to 
indicate the molecular weight of proteins. After electrophoresis, proteins were 
transferred to Hybond PVDF membranes (Amersham Pharmacia Biotech, Piscataway, 
NJ) using a Semi-Dry Electrophoretic Transfer Cell (Bio-Rad Laboratories, Hercules, 
CA). Briefly, the gel was equilibrated in 200 ml of 1 x transfer buffer (pH9.2) 
containing 48mM Tris, 39mM glycine, 20% methanol, and 0.037% SDS, and 
meanwhile, the PVDF membrane of gel size was also soaked in the 1 x transfer buffer 
in a separate container for 5-10 min after activating it with methanol. A sandwich was 
assembled by putting a sheet of extra thick filter paper (Bio-Rad, Hercules, CA) pre-
soaked in 1 x transfer buffer onto the platinum anode, followed by the pre-wetted PVDF 
membrane, and air bubbles should be carefully removed from between each layer. After 
the cathode and the safety cover were placed onto the stack, the electrophoretic transfer 
was performed at a constant 20V for 30 min. 
The blotted membrane was removed and blocked in 5% non-fat milk in TBST 
buffer (20 mM Tris, 150 mM NaCl, 0.1% Tween 20, pH 7.6) by incubating at 4°C 
overnight with gentle shaking. The blot was incubated with a primary antibody for 1 
h with shaking. Antibodies against V5-tag (Invitrogen, USA), CRH-BP, (Santa Cruz 
Biotechnology, Santa Cruz, CA) were used as primary antibodies in this study for 
protein detection. Equal loading of protein samples was verified with antibodies to ß-
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actin (Chemicon International). Unbound antibodies were removed by briefly rinsing 
the membrane with two changes of TBST buffer, the membrane was thoroughly 
washed with sufficient TBST buffer (>4 ml/cm2) by shaking at RT for 10 min and for 
a total of three times. Horseradish peroxidase (HRP) conjugated rabbit anti-goat Ig 
(Dako A/S, Glostrup, Denmark) at 1: 10,000 dilution was prepared and reacted with 
the blot at RT for 1 h. after repeating the washing steps as the previous time, the 
proteins were visualized by chemiluminescence using an ECL Plus Western blotting 




2.6.5 Cell proliferation and colony formation assay  
 
 HCC cell lines HepG2, and Hep3B were seeded overnight in a 6-well plate 
and were transiently transfected with either pDEST40-CRH-BP/V5 plasmid or 
pDONR-221 empty vector. The cells were harvested 24 hours after transfection and 
proportionally replated into 96-well plate in triplicates and cultured for an additional 
two days. The cell growth rate was measured daily by using a modified MTT assay 
(WST-1 reagent, Roche) according to the manufacturer’s protocol. Cell number was 
determined by comparison to corresponding standard curves established by using the 
value of absorbance at 450 nm against known number of cells tested. HepG2 cells 
harvested 24 hours after the above-mentioned transfection were used for anchorage-
independent colony formation assay. 0.5-1 x 104 cells suspended in 0.25 ml of 0.35% 
agar-DMEM /10%FBS were plated in 24-well plate in triplicates overlying a 0.7% 
agar bottom layer and cultured at 37°C with 5% CO2. Two to three weeks later, the 
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colonies were stained with p-iodonitrotetrazolium (1 mg/ ml, Sigma) and 
photographed under an MZFL3 stereomicroscope (Leica Microsystems, Heidelberg, 
Germany). Colonies > 100 µm in diameter were counted and analyzed using the Leica 
QWin imaging software.   


























3 RESULTS & DISCUSSION 
 
3.1 PART I: Expression of CRH-BP in HCC and normal tissue  
 
 
The lack of good molecular markers for HCC has rendered the disease a major 
challenge for diagnosis and prognosis. Currently, the presence of a liver mass on 
radiologic investigations and the detection of an elevated level of serum alpha 
fetoprotein (AFP) are the two main means of diagnosing HCC. Genome-wide 
analysis by microarray offers a systematic approach to uncover comprehensive 
information about the transcription profile of HCC (Brown et al., 1999). In a previous 
study, complementary DNA (cDNA) microarrays were used to examine the global 
cellular changes in matched pairs of HBV-associated HCC tumour and non-tumour 
liver tissue specimens of 37 patients (Neo et al., 2004). A further comparison was 
performed with other independent microarray studies of HCC in an attempt to 
identify a composite cassette of discriminator genes that could potentially serve as 
tumour markers. CRH-BP was one of the 218 genes that were significantly 
differentially expressed between HCC tumour and non-tumour tissue. Based on these 
backgrounds, this study was initiated to confirm the down-regulation of CRH-BP in 
HCC and to explore the possible reason behind this phenomenon.  
 
3.1.1 Total RNA extraction 
All 37 patients (from whom the test set of tissue specimens was derived) had 
HBV-associated HCC and underwent curative liver resection. The paired samples of 
tumour and corresponding non-tumour tissue specimens were obtained from the 
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frozen resected liver specimen. Trizol reagent (Life Technologies, Bethseda, MD) 
was used to isolate total RNA from the frozen tissue specimens. Total RNA from 14 
HCC cell lines was also extracted using the commercialized RNA isolation kit. About 
2 µg of each RNA sample was used for cDNA synthesis in a total of 20 µl reaction. 
 
3.1.2 RT-PCR 
To detect the mRNA expression of CRH-BP, a sensitive RT-PCR was 
established. Tissue from non-tumourous organ samples was used as a positive control 
for the detection of the gene. Namely, normal tissue from the brain and liver were 
selected as positive control, as expression of CRH-BP was confirmed to be the most 
abundant in these organs. Figure 9A indicates the location of the primers for the gene 
in RT-PCR and the size of the expected DNA fragment amplified from the reaction.  
During the first round of RT-PCR, a different set of primers was used. These 
amplified a smaller fragment of the CRH-BP gene (~300bp). Surprisingly, the 
fragment was also amplified in most of the HCC cell lines tested and was rendered 
unspecific to the CRH-BP gene. A different set of primers was then designed to 
amplify a larger fragment of the gene. After several rounds of RT-PCR, the reaction 












      Exon 1               2       3       4                5                      6                        Exon 7  
  CRH-BP-fwd  3’                                                                                   5’ CRH-BP-rev 
 
        1   2 3 4 5 6  
            730bp  
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Figure 9. Establishment of RT-PCR. A. Primers used to detect the expression of 
CRH-BP gene. The location of the sense (3’) and anti-sense (5’) primers for the gene 
are shown as triangles. The positions of the introns and exons are also shown in the 
picture. Introns are represented by the straight lines and exons by the rectangular 
boxes. B. The 730bp fragment, the result of the RT-PCR, spans from exon 1 to exon 
6. 
 




3.1.3 Expression of CRH-BP gene in HCC tissues 
Using real-time PCR followed by RT-PCR amplification, CRH-BP gene 
expression in HCC tissues was investigated in eight randomly selected HCC patients. 
These samples were taken from the 37 matched pairs of HBV-associated HCC 
tumour and non-tumour liver tissue specimens used in the microarray study. As 
presented in Figure 10, there was a overall decrease in expression of CRH-BP in the 
tumour tissues compared to the paired non-tumour tissues in all the samples tested. 
The reduced folds of CRH-BP expression for each pair of samples were highly 
correlated to the values revealed by the previous cDNA microarray study.  
A similar profile of the CRH-BP gene expression was observed using regular 
reverse transcription PCR.  The primers used specifically amplified the CRH-BP 
gene, further confirming that CRH-BP was distinctively down-regulated in cancer 
tissues compared to their complimentary normal tissues. These results also verify the 




















Figure 10. Down-regulation of CRH-BP in HCC tissue samples  
 
(A) Quantitative real-time PCR analysis revealed a down-regulation of expression in 
HCC tumours. Total RNA samples from 8 pairs of HCC tumour (T) and 
corresponding non-tumour (N) tissues were randomly selected from 37 pairs of 
samples previously collected for a cDNA microarray study.  
The fold change indicates the relative expression of CRH-BP (tumour: non-tumour) 
in each patient. The negative values show a decrease in expression in tumour tissue 
relative to the corresponding non-tumour tissue.  
(B) Semi-quantitative RT-PCR analysis confirmed the results of the real-time PCR 
showing that CRH-BP expression is down-regulated in tumour tissues compared to 












3.1.4 Expression of CRH-BP in hepatoma cell lines and normal tissue 
For further verification that CRH-BP expression is down-regulated in liver 
cancer, RT-PCR was performed on 14 hepatoma cell lines. RNA was extracted from 
all 14 cell lines, namely HA22T, Hep3B, Huh1, Huh4, Tong, PP5, SNU182, 
SNU449, SNU475, Huh6, Huh7, HepG2, Mahlavu and SK-Hep-1.  The cDNA 
synthesized from the RNA samples was used as the template for the RT-PCR. To 
prevent genome contamination, all RNA samples were treated with DNase prior to 
RT-PCR. In addition, the primers spanning several introns further ensured the mRNA 
origin of the PCR products. All samples were run at the same time to make certain all 
other experimental conditions were maintained and any difference in expression of 
CRH-BP was genuine.  
Repeated RT-PCR results revealed that the CRH-BP transcript was 
undetectable in all the 14 HCC cell lines tested (Figure 11A) and was ubiquitously 
expressed in the 15 human normal tissues that were tested (Figure 11B). As expected, 
expression of CRH-BP was especially strong in the liver tissue for CRH-BP was 
known to be of hepatic origin. GAPDH, a house-keeping gene, was used as a positive 














Figure 11. Undetectable expression of CRH-BP in HCC cell lines compared to 
obvious expression in normal tissue.  
 
  (A) Repeated semi-quantitative RT-PCR analysis revealed that CRH-BP expression 
was not detected in any of the 14 HCC cell lines tested.  
(B) All 15 types of normal human tissues expressed CRH-BP. GAPDH was used as 















3.1.5 Expression of CRH-BP in other cancer cell lines 
 
  
 To test if the down-regulation of CRH-BP is only specific to HCC or is a 
phenomenon that is rampant in all other types of cancers, expression of the gene was 
tested in several other cancer cell lines. Five different types of cancers- colon cancer, 
breast cancer, nasopharyngeal cancer (NPC), lung cancer and glioblastoma were 
chosen. Total RNA was extracted from all 10 cell lines and cDNA synthesised. RT-
PCR was carried out to determine CRH-BP expression. Figure 12 shows that CRH-
BP expression was only detected in two out of four breast cancer cell lines tested. All 
other cancer cell lines showed no expression, the same result as the 14 HCC cell 
lines. All the experiments carried out used the same PCR programme and were 
repeated several times with normal tissue from the liver as a positive control. GAPDH 
was used as an internal control to ensure the quality and quantity of the RNA.  
 Since only a few cell lines from each cancer could be obtained for this study, 
the results are not exhaustive. But based on what was observed, we can presume that 
the down-regulation of CRH-BP is not specific only to liver cancer and is something 
that can be seen in many other types of cancers. Expression of the gene in two out of 
the four breast cancer cell lines shows that down-regulation of CRH-BP is not 






















Figure 12. Expression of CRH-BP in other cancer cell lines. Conventional RT-
PCR revealed that the expression of CRH-BP was down-regulated in most other 
cancer cell lines as well. Only T47D and MB231 breast cancer cell lines showed a 



























 A system was established to study the expression of CRH-BP in both HCC 
tissues and hepatoma cell lines. A previous microarray study done in the laboratory, 
identified a total of 493 genes, which showed a significant differential expression in 
tumour tissue as opposed to non-tumour tissue. Out of these 493 genes, 218 genes 
showed a 1.5-fold change in gene expression and displayed the smallest (best) P 
value scores (P < 1x 106) (Neo et al., 2004). CRH-BP was one of these 218 candidate 
genes with potential to be a diagnostic HCC marker. CRH-BP was also shown to be 
differentially expressed in tumour tissue compared to non-tumour tissue in another 
global study done by Chen et al. (2002). To further validate the microarray data, real 
time RT-PCR analysis was performed for CRH-BP in eight randomly selected 
samples from the 37 samples that were used in the previous study.  
 Expression of CRH-BP was confirmed to be significantly down-regulated in 
all the eight tumour samples tested relative to the complementary non-tumour 
samples using both real-time RT-PCR and conventional RT-PCR. A strong 
expression of the gene was observed in all 15 different normal tissues tested. All 14 
HCC cell lines tested showed no detectable expression of CRH-BP. It can thus be 
safely confirmed that CRH-BP expression is definitely down-regulated in liver 
cancer. 
 The absence of CRH-BP gene expression in eight out of the ten cell lines from 
cancers other than liver cancer tested proved that the down-regulation of CRH-BP is 
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not specific to HCC.  But the presence of a CRH-BP signal in two out of the four 
breast cancer cell lines tested confirms that it cannot be used as a global cancer 
diagnostic marker. To further validate these results, more cell lines from each cancer 
have to be tested. This will make the results more exhaustive and conclusive.  
 In conclusion, CRH-BP persists to be undetected in all HCC cell lines and 
tumour tissues tested relative to the normal and non-tumour tissue. Since it was also 
undetected in a few colon, breast, lung, nasopharyngeal and glioblastoma cancer cell 
lines, this phenomenon is not specific to HCC. The down-regulation of CRH-BP is 
thus a trend that can be observed in most cancers. 
 In order to confirm the down-regulation of CRH-BP gene in HCC tumour 
tissues and HCC cell lines, the CRH-BP protein level in HCC tumour tissues and 
HCC cell lines has to be determined. This is to ensure the down-regulation of the 
gene expression is translated into the expected down-regulation of the protein level. 
Lysate from the 14 HCC cell lines and HCC tumour and non-tumour tissue should be 
separated on a 10% SDS-polyacrylamide gel electrophoresis, and transferred to a 
PVDF membrane. The membrane should then be incubated with primary antibodies 
specific against CRH-BP for the detection of the CRH-BP protein. Carrying out a 
western blot with a CRH-BP specific antibody as described above will provide an 
accurate measure of the CRH-BP protein level in the 14 HCC cell lines and HCC 








3.2 PART II: DNA hypermethylation of CRH-BP. 
 
 
 As demonstrated in the previous study, mRNA expression of CRH-BP gene 
seemed to be down-regulated in both HCC tissues and cell lines. There could have 
been several reasons behind the gene silencing. The most probable causes are either 
mutations in the gene or of epigenetic origin. Epigenetic silencing is a more common 
mechanism of gene inactivation than mutation (Stebbing et al., 2006).  Epigenetic 
modifications of DNA that influence gene expression include methylation, acetylation 
and phosphorylation of histones and methylation at CpG dinucleotides. Out of these, 
the easiest and most frequently studied mechanism is methylation of CpG 
dinucleotides (Feinberg et al., 2004).  
 To explore the possibility of CpG island hypermethylation being the cause for 
CRH-BP gene silencing, a methylation study was carried out. First, the location of a 
CpG island within the promoter region was identified using a computer software, 
MethPrimer.  Methylation specific PCR (MSP) was then performed with primers 
specifically designed to only amplify regions that were methylated. MSP was done on 
both HCC tissue samples and HCC cell lines.  
 For further conformation of the occurrence of CpG island hypermethylation, 
the HCC cell lines were treated with 5-Aza-dC, a demethylating agent. Any 








3.2.1 In silico study of the CpG island within the 5’ region of CRH-BP 
 
 
Before carrying out the methylation study, an in silico examination was first 
performed to identify and locate the CpG island in the CRH-BP gene. A web-based 
programme called MethPrimer was used for this purpose. Any region that had a GC 
content greater than 60% and a length of more than 200bp was identified. Another 
programme, Primo MSP 3.2 was also used to confirm these results and to design 
primers that would specifically amplify the methylated region.  
The results generated showed that a CpG-rich island was present spanning 
exon 2 and intron 3 of the CRH-BP gene. It had a GC content of more than 70% and 
was about 500bp in length. In order to examine if the methylation status influences 
CRH-BP expression in HCC cells, we have defined the precise location and 




Figure 13.  The location of the CpG island in CRH-BP. The CpG island was found 
in exon 2 and intron 3 of CRH-BP gene with the aid of MethPrimer. The region-
shaded is the CpG island. 
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3.2.2 Bisulfite treatment 
  Isolation of high-quality genomic DNA is critical, as the DNA must be 
sufficiently pure to ensure complete conversion by sodium bisulfite (Warnecke et al., 
2002). The QIAGEN DNeasy Kits provide high-quality genomic DNA from animal 
samples. RNase was added to ensure only the genomic DNA was eluted and any traces 
of RNA removed.  
  Following DNA isolation, MethylEasy™ DNA Bisulphite modification kit 
was used to carry out the chemical modification of the DNA. In the bisulfite treatment 
all cytosines are converted to uracil but those that are methylated (5-methylcytosine) 
are resistant to this modification and remain as cytosine (Wang et al., 1980). This 
altered DNA can then be amplified by MSP. This kit provides rapid and efficient 
bisulfite conversion. Figure 14 illustrates how bisulfite treatment affects the DNA and 
the subsequent steps to the treatment.  
 
Figure 14. Illustration of MSP. Bisulfite treatment converts all non-methylated 
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3.2.3 Methylation status of CpG island in 5’ region of Glutathione S-
transferase (GSTP1) gene in 14 HCC cell lines 
 
Methylation Specific PCR (MSP) is a technology for the sensitive detection of 
abnormal gene methylation utilizing small amounts of DNA. It is a bisulfite 
conversion based PCR technique for the study of DNA CpG methylation. For MSP 
experiment, two pairs of primers are needed with one pair specific for methylated 
DNA (M) and the other for unmethylated DNA (U). To achieve discrimination for 
methylated and unmethylated DNA, in each primer (or at least one of the pair) 
sequence, one or more CpG sites are included. First, DNA is modified with sodium 
bisulfite and purified. Then, two PCR reactions are performed using M primer pair 
and U primer pair. Successful amplification from M pair and U pair indicate 
methylation and unmethylation respectively. 
The occurrence of GSTP1 hypermethylation in the 14 HCC cell lines were 
analysed using MSP assay. GSTP1 was used as a positive control for it had been 
proven to be epigenetically silenced by CpG island DNA hypermethylation in HCC 
(Zhong et al., 2002). In his study, Zhong et al. (2002) used MSP analysis to show that 
CpG island hypermethylation was associated with the transcriptional silencing of 
GSTP1 in human Hep3B and HepG2 cell lines.   
In this study, the methylation status of GSTP1 in all 14 hepatoma cell lines 
was determined. The sequences for the two sets of primers and the optimised PCR 
programme was obtained from a previous study done by Jhaveri et al. (1998). A 
methylated product of 97bp and an unmethylated product of 91bp were expected. As 
can be seen in Figure 15, GSTP1 was observed to be partially methylated in Huh1, 
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Huh4 and Sk-Hep-1 for there was a band seen with both sets of primers. Complete 
methylation is evident in six cell lines Hep3B, Tong, SNU182, SNU475, HepG2 and 
Mahlavu where a signal was only seen with the methylated primers. No expression 
was observed at all in HA22T, Huh6 and PP5. These results prove that the 
methylation status of GSTP1 may vary in different HCCs and may not be the only 
reason behind the silencing of the gene. It also shows that GSTP1 can be found in 














Figure 15. Analysis of the methylation status of the GSTP1 CpG island by MSP 
in HCC cell lines. The presence of a visible PCR product in lane U indicates the 
presence of the unmethylated GSTP1 gene and the presence of product in lane M 
indicates the presence of the methylated GSTP1 gene. Hep3B, Tong, SNU182, 
SNU475, HepG2 and Mahlavu are hypermethylated at GSTP1 gene whereas Huh1, 
Huh4 and Sk-Hep-1 are partially methylated at the GSTP1 gene. No expression of the 
methylated or unmethylated fragment was observed in HA22T, Huh6 and PP5. Water 
was used as a negative control. M: Methylation. U: Unmethylation. 
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3.2.4 Methylation status of CpG island in 5’ region of CRH-BP gene in 14 HCC 
cell lines 
MSP analysis was performed on all 14 HCC cell lines to determine the 
methylation status of the gene CRH-BP. Bisulfite treatment was done on the genomic 
DNA of all 14 HCC cell lines and primers were designed to distinguish methylated 
and unmethylated CRH-BP in the bisulfite-modified DNA, taking advantage of the 
sequence differences resulting from the bisulfite modification. GSTP1 was used as a 
positive control to confirm that the entire DNA was modified.  
Representative results of the gel analysis of bisulphite-treated DNA samples 
amplified with methylated- and as a control for the bisulphite modification process, 
nonmethylated-specific primers are shown in Figure 16. These primers were designed 
using the MethPrimer software, which also predicted the 5’CpG island of CRH-BP. 
The 5’CpG island of CRH-BP was demonstrated to be completely methylated in cell 
lines HA22T, SNU182, SNU449, HepG2, Mahlavu and SKHep-1. Partial methylation 
was observed in Hep3B, Tong, PP5, SNU475, Huh6 and Huh7. Huh1 showed greater 
expression of unmethylated than methylated CRH-BP and the CpG island of CRH-BP 
in Huh4 seemed to be completely unmethylated. To recap, the results in Figure 11 
confirmed that CRH-BP expression was silenced in all the 14 HCC cell lines tested. 
However, the results of the MSP analysis (Figure 16) showed that methylation of 
CRH-BP is not observed in all 14 HCC cell lines tested. It may thus be a possibility 
that there are either other factors involved in silencing of the CRH-BP gene in these 
cell lines where CRH-BP is shown not to be methylated or MSP analysis was not 
sensitive enough to detect the methylation in these cell lines. Methylation of the CpG 
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island though seems to be the main reason behind the down-regulation of CRH-BP 
expression in HCC cell lines as 12 out of 14 cell lines tested had strong methylation 
as shown by the MSP analysis and all had no expression of CRH-BP as shown in 
Figure 11. 
 
3.2.5 CRH-BP CpG island hypermethylation in HCC tissue samples 
 
To study whether CRH-BP CpG island hypermethylation changes led to the 
absence of its expression in human HCC cells, a series of six HBV-associated HCC 
tissue samples were randomly selected from the original 37 sets that were used for the 
microarray analysis and analysed for CRH-BP CpG island DNA hypermethylation. 
The CpG island hypermethylation status was surveyed using MSP. Representative 
results of the application of the assay to the analysis of CRH-BP are displayed in 
Figure 17. 
The 5’CpG island of CRH-BP was demonstrated to be hypermethylated in 
five out of the six HCC tumours, whereas in the corresponding non-tumourous liver 
tissues, CRH-BP hypermethylation was not detected at all. Case 1 shows that CRH-
BP was hypermethylated in tumour tissue but not its corresponding non-tumour 
tissue. Case 2 and Case 4 produced similar results where partial methylation was 
observed in the tumour tissues only and the paired non-tumour tissue only had 
unmethylated copies of the gene. Case 3 and Case 6 both appear to have no 
unmethylated or methylated CRH-BP in their normal tissue. This could be due to 
degradation of the gDNA of the these tissues because of improper storage for the 
same result was obtained after several attempts. The CRH-BP gene in Case 5 
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appeared to be unmethylated in both tumour and non-tumour tissue as a signal was 
only observed with the unmethylated primers. 
The presence of the unmethylated CRH-BP DNA taken together with the 
MSP results of Huh4 shows the possibility of another mechanism that may play a role 
in silencing the expression of CRH-BP. But since the 5’ CpG island of CRH-BP was 
demonstrated to be hypermethylated in five (83%) out of the six tumours tested, and 
no hypermethylation was observed in any of the corresponding non-tumourous liver 
tissues, we can safely conclude that methylation of the CpG island is the main 

















Figure 16. MSP analysis of CRH-BP. MSP analysis revealed that the 5’CpG island 
of CRH-BP was hypermethylated in almost all cell lines except Huh4. The results 
showed partial methylation of the gene in cell lines Hep3B, Huh1, Tong, PP5, 
SNU475, Huh6 and Mahlavu. Distilled water was used as a negative control. M: 























Figure 17. MSP analysis of bisulfite-treated tissue. Bisulfite-treated DNA was used 
for PCR amplification using primer sets designed for methylated (M) and 
unmethylated CRH-BP (U). Cases 1, 3, 4 and 6 are hypermethylated at CRH-BP 




3.2.6 De-methylation of the GSTP1 CpG island by 5-Aza-dC activates GSTP1 
expression 
 
To establish the experimental set up for the restoration of gene expression by 
using 5-Aza-dC treatment, a demethylating agent, GSTP1 was again used as a 
positive control. Past studies have proven its expression to be restored in several HCC 
cell lines treated with 5-Aza-dC and other demethylating agents. Hep3B and HepG2 
are just two of these HCC cell lines and they were thus selected for this current study. 
Firstly the expression of GSTP1 in all 14 HCC cell lines was determined 
using RT-PCR. Figure 18 shows that GSTP1 was only shown to be expressed in half 
the HCC cell lines tested. No expression was observed in Hep3B and HepG2. 
Therefore they were the best candidates to be used for establishing the experimental 
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set up.  GAPDH was again used as an internal control to ensure the quality and 
quantity of the RNA was good.  
Hep3B and HepG2 were first seeded at a density of 2 x 105 and 4 x 105 cells 
into a 6-well plate respectively. Twenty-four hours later cells were treated with 5µM 
and 10 µM 5-Aza-dC (Sigma). Total RNA was isolated from the cells at 72h, 96h and 
120h after addition of 5-Aza-dC. The media was changed every 48h.  RT-PCR was 
used to determine the expression of GSTP1 after treatment with the demethylating 
agent. Expression of GSTP1 was restored in both HepG2 and Hep3B cell lines within 
the first 72hrs with only 5µM concentration of 5-Aza-dC (Figure 19). The signal got 
stronger with increased length of exposure to 5-Aza-dC and at higher concentrations. 












Figure 18. Expression of GSTP1 in all 14 HCC cell lines. Only 7 out of the 14 
hepatoma cell lines tested showed expression of GSTP1. Hep3B and HepG2 showed 
no expression at all and were thus best candidates for establishing the experimental 





Figure 19. Restoration of GSTP1 expression after 5-Aza-dC treatment in HepG2 
and Hep3B.  After treatment with 5-Aza-dC, expression was restored in both HCC 
cell lines tested. Re-establishment of the expression took place within the first 72 h of 
treatment. As the length of exposure to the treatment increased, so did the strength of 
the GSTP1 signal. An increase in concentration of the drug also increased its 










3.2.7 De-methylation of the CRH-BP CpG island by 5-Aza-dC activates its 
expression 
 
Once the experimental set up was established, all 14 HCC cell lines were 
seeded at a density of 3x 105 – 4x 105 cells/6-well plate. Total RNA was isolated from 
the cells at 72h, 96h and 120h after addition of 5-Aza-dC. 
Without treatment with 5-Aza-dC, CRH-BP expression was non-existent in all 
the 14 HCC cell lines. RT-PCR showed obvious restoration of CRH-BP mRNA 
expression in HA22T, Hep3B, Huh1, Tong, SNU449, Huh6, Huh7, Mahlavu and 
SKHep-1. A 5 µM concentration of 5-Aza-dC was sufficient to de-methylate CRH-
BP in all cell lines. Expression was re-established in PP5 only after four days of 
treatment and in cell lines Huh4, SNU182 and SNU475, there was no restoration of 
CRH-BP mRNA expression observed at all (Figure 19).  The lack of restoration of 
CRH-BP expression in Huh4 correlates with the MSP results where the gene was 
shown to be completely unmethylated in Huh4. Therefore, another mechanism is 
involved in silencing of CRH-BP in Huh4. 
 
 






Figure 20. Restoration of CRH-BP expression after 5-Aza-dC treatment.  After 
treatment with 5-Aza-dC, expression was restored in almost all the 14 HCC cell lines 
except for Huh4, SNU182 and SNU475. Expression was only re-established in PP5 










 A reliable system was established in this study to comprehensively examine 
the methylation status of the CpG island promoter region of CRH-BP. CpG islands 
are associated with genes, particularly housekeeping genes. Normally, a cytosine (C) 
base followed immediately by a guanine (G) base is rare in vertebrate DNA because 
the C in such an arrangement tends to be methylated (Gardiner-Garden et al., 1987). 
CpG dinucleotides are not randomly distributed throughout the vast human genome 
and have hypothesised to have evolutionary origin. CpG rich regions, known as CpG 
islands are usually unmethylated in all normal tissues and frequently span the 5’ 
region (promoter, untranslated region and exon 1) of a number of genes (Esteller, 
2005). Methylation has been postulated as a mechanism for silencing tissue-specific 
genes in cell types where they should not be expressed and in gender specific genes. 
Transcriptional silencing of tumour suppressor genes by CpG island promotor 
hypermethylation is thus an epigenetic aberration that may be involved in tumour 
formations. 
 Two sets of experiments were carried out to confirm the hypothesis. One was 
MSP and the other the restoration of gene expression through 5-Aza-dC treatment. 
The experimental systems for both sets of tests were established using GSTP1 as the 
positive control. GSTP1 is a suitable choice for a positive control as it has been 
recognised to be hypermethylated in HCC (Tada et al., 2005; Zhong et al., 2002). 
MSP analysis of the HCC cell lines revealed CRH-BP to be hypermethylated 
in six out of the 14 cell lines tested. As a weak band was also seen with the use of the 
primers specific to the unmethylated region of CRH-BP in six of the cell lines, it was 
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interpreted as partial methylation. The results suggest that not all CpG sites in the 
CRH-BP gene are equally methylated. But, methylation of the CpG island seems to 
be the main reason behind the down-regulation of CRH-BP expression in HCC cell 
lines. These results were confirmed with MSP analysis of liver tumour tissues where 
five out of the six cases tested showed a strong signal with primers specific to the 
methylated region. One case revealed that the CRH-BP gene was unmethylated in 
both tumour and the complementary non tumour tissue. This suggests that there may 
be other mechanisms of gene silencing such as the presence of non-coding RNA, 
histone modification or chromatin remodelling taking place. 
Treatment of the 14 HCC cell lines with 5-Aza-dC results in simultaneous de 
novo synthesis of CRH-BP RNA for 11 out of the 14 cell lines. These results provide 
compelling evidence that methylation silences CRH-BP expression and that 
demethylation or hypomethylation permit transcriptional activation of the gene. 
Together, this data suggests that CRH-BP is usually transcriptionally repressed 
mainly due to promoter hypermethylation. 
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3.3 PART III:  Over-expression of CRH-BP in HCC cell lines and its effect on cell 
proliferation 
 
To examine the potential biological function of CRH-BP in hepatic 
carcinogenesis, some functional assays were carried out. Its capability in playing a 
role in cell proliferation was tested using WST-1 assay and an anchorage-independent 
assay. The full open reading frame (ORF) of CRH-BP was cloned into an expression 
plasmid pcDNA- DEST40 tagged with V5-epitope. The recombinant plasmid 
pDEST40-CRH-BP/V5 was then transfected into HepG2 and Hep3B HCC cell lines. 
As CRH-BP is a secreted protein, its presence was also detected in the supernatant. 
The effect of CRH-BP expression on cell growth in liquid culture was measured by 
WST-1 assay.  
To further confirm CRH-BP’s role in cell proliferation, an anchorage-
independent assay to examine colony formation ability in soft agar culture was 
performed. HepG2 cells transfected with pDONR-221 and those transfected with 
pDEST40-CRH-BP/V5 were counted and the differences determined to be 
significant. The results from both experiments are sufficient to conclude CRH-BP’s 
role in cell proliferation. 
 
3.3.1 Plasmid construction 
For over-expression of CRH-BP in both Hep3B and HepG2 cells, transfection 
of the gene had to be done. The full length of CRH-BP ORF (1837bp) was cloned 
into an expression plasmid pcDNA- DEST40 tagged with V5-epitope for detection. 
pcDNA-DEST40 is a 7.1 kb vector derived from pcDNA3.1/V5-His™ and adapted 
Results & Discussions 
 
 -71- 
for use with the Gateway™ Technology. It is designed to allow high-level, 
constitutive expression of the gene of interest in a variety of mammalian hosts. The 
full-length CRH-BP was first cloned into an entry vector using pENTR Directional 
TOPO® Cloning Kit. Each entry clone contains attL sites flanking the CRH-BP gene.  
The gene in the entry clone is then transferred to the destination vector backbone 
(pcDNA-DEST40) by mixing the DNAs with the Gateway™ LR Clonase™ enzyme 
mix. The resulting recombination reaction is then transformed into E. coli and the 
expression clone selected. True expression clones will be ampicillin-resistant and can 
be picked out from an LB-ampicillin plate.  
The illustrative structure of the constructed plasmid is shown in Figure 21. 
DNA from the entry clone including the CRH-BP ORF replaces the region between 
bases 918 and 2601. This is at the attR1 recombination site. 
  
 
5’  T7          1         1837   3’ 
 
Figure 21. Plasmid construction. Full length ORF (1837bp) was amplified by RT-
PCR and cloned into an entry clone before cloning it into the pcDNA-DEST40 vector 
as pDEST40-CRH-BP/V5. This cloned gene was used for transfection into Hep3B 
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3.3.2 Expression of CRH-BP after transfection 
Expression of CRH-BP from the expression clone can be performed in 
transiently transfected cells. To facilitate separation and visualization of the 
recombinant fusion protein western blot was carried out. Since CRH-BP is a secreted 
protein, the supernatant was also collected after the transfection to detect the presence 
of CRH-BP. 
Figure 22 shows that CRH-BP was successfully over-expressed in both cell 
lines HepG2 and Hep3B. CRH-BP expression was undetectable in cells that were not 
transfected with the plasmid. There was a stronger signal in Hep3B cell lines 
compared to HepG2. This seems to show that the transfection was more effective for 
Hep3B than HepG2 cell lines. A high transfection efficiency in Hep3B and a lower 
transfection efficiency in HepG2 both resulted in the same results in the various 
functional assays carried out thus confirming that the transfection efficiency does not 
appear to affect the results of the functional assays. The results however confirmed 
that CRH-BP was secreted into the supernatant. β-actin was used as a positive control 
to confirm that the quantity and quality of the lysate was good. 
  
3.3.3 Results of WST-1 assay on Hep3B and HepG2 cell lines 
The Cell Proliferation Reagent WST-1 is a ready-to-use substrate which 
measures the metabolic activity of viable cells. The colorimetric assay is based on the 
reduction of WST-1 by viable cells. The reaction produces a soluble formazan salt. 
This method is very suitable and accurate in measuring cell proliferation. The 
formazan dye in the microplate is quantitated with an ELISA plate reader and the 
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absorbance directly correlates with the cell number. 
Figure 23 shows that the cell number of the control, untransfected cells and 
CRH-BP transfected cells are the same after 6 days of transfection. Whatever slight 
difference seen was statistically insignificant. This shows that CRH-BP does not play 






Figure 22. Westeren blot analysis to confirm over-expression of CRH-BP in cell 
lines. Western Blot confirmed the forced expression of CRH-BP/V5 protein in 
Hep3B and HepG2 cells. pDEST40-CRH-BP/V5 or pDONR-221 plasmids were used 
to transfect the cells and cell lysates and surrounding media were collected 48h after 
for immunoblot analysis by specific anti-V5-tag antibody. ß-actin was used as loading 




Figure 23. Effect of CRH-BP on cell proliferation. No effect of CRH-BP on cell 
growth in liquid media. pDEST40-CRH-BP or pDONR-221 transfected cells were 
harvested 24h after transfection and proportionally replated into 96-well plates. 
Growth rates at indicated time points were measured in triplicates by WST-1 reagent.  
 




3.3.4 CRH-BP and anchorage independent growth of HepG2 cells 
Most metazoan cell type requires a surface on which to flatten out and divide, 
even if the final stage (cytokinesis) is to all but loose contact with it.  This is 
anchorage dependence of growth, a control to cell division that many transformed 
cells loose. The ability to grow on "soft agar" is a routine test taken as an indication 
that cells with this ability are anchorage independent. Anchorage-independence 
correlates strongly with tumourogenicity and invasiveness in several cell types, such 
as small-cell lung carcinoma (Carney et al, 1980).  Many types of normal cells are 
programmed to undergo apoptosis if they are prevented from contacting other cells 
(http://www.bms.ed.ac.uk/research/others/smaciver/Cell%20biol.topics/anchorage_de
pendence_of_growth.htm). 
To thus study the tumourogenicity and invasiveness of CRH-BP in HepG2 
cells, an anchorage independent growth assay was carried out. There was 
insignificant difference in the growth of the HepG2 cells that were transfected with 
pDEST40-CRH-BP and pDONR-221, the control, as can be seen in Figure 24. Since 
the number of colonies formed were almost the same, CRH-BP can be concluded to 




















Figure 24. Anchorage independent growth of HepG2 cells. CRH-BP had no effect 
on anchorage-independent growth of HepG2 cells in colony formation assay. The 
HCC cell lines transfected with either pDEST40-CRH-BP/V5 or pDONR-221 control 
showed no difference in the number of colonies formed under microscope after p- 
iodonitrotetrazolium staining. The colony number formed in pDONR-221 control 
























Since CRH-BP was confirmed to be down-regulated in HCC cell lines and 
tissues as well as other cancer cell lines, it would be interesting to find out its actual 
role in tumour development. WST-1 assay and anchorage-independent assay were 
performed to determine its possible role in cell proliferation.  
Assays to assess the proliferative activity of cells grown in culture or 
harvested from tissue samples are a core tool for monitoring the health and growth 
rate of a cell population. Historically, cell proliferation assays relied on the detection 
of tritiated thymidine 3H uptake. However, the divergence of trends away from the 
use of radioactivity and toward assay platforms compatible with automated sample 
handling, high-throughput screening in microtiter plates, and, more recently, high-
content screening (HCS) using live cell assays to image cell function, metabolism, 
and signaling at the level of the individual cell has led to an expanded range of assay 
formats for measuring cell proliferation. These include fluorescent, luminescent, and 
colorimetric assays that can determine cell count, detect DNA synthesis, or measure 
metabolic activity. WST-1 assay and anchorage-independent assay were selected for 
their ability to carry out automated high-throughput screening with ease. The results 
are also very accurate compared to other methods. 
As can be seen in the results generated from both experiments, CRH-BP is not 
involved in cell proliferation. To confirm these results, both assays should be carried 
out on a few other cell lines. Other functional assays should also be performed to find 
out its possible function. 



























4 GENERAL DISCUSSION AND CONCLUSIONS 
 
 
This study describes the expression of CRH-BP in all normal tissues and 
its down-regulation in liver cancer tissues and cell lines using cDNA microarray, 
real time PCR and regular reverse transcription PCR (RT-PCR). In addition, to 
study the reason behind the silencing of CRH-BP, a methylation study was done. 
Both MSP analysis and 5-Aza-dC treatment were carried out. The analysis of the 
results revealed for the first time that epigenetic silencing of CRH-BP did take 
place and DNA methylation was the cause of it. In an attempt to determine the 
role CRH-BP may play in cancer, two cell proliferation assays were carried out. 
They included WST-1 assay and an anchorage-independent assay.   
Both, assays showed no difference in growth between the mock-
transfected controls and the CRH-BP over-expressed cells. Accordingly, the gene 
CRH-BP is probably not involved in the process of cell proliferation. CRH-BP 
may thus play a different role in tumourgenesis.  
As the chief regulator of circulating CRH in the blood, hepatic CRH-BP 
plays a fundamental role in the downstream events of CRH. In this manner, it has 
a secondary influence on a myriad of pathological conditions of the cell. A higher 
expression of CRH has been observed in thyroid carcinomas (Scopa et al., 1994), 
breast cancers (Ciocca et al., 1990) and adrenocortical tumourgenesis (Willenberg 
et al., 2005). The down-regulation of CRH-BP may be the reason for such a 
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phenomenon. An epigenetic gene silencing mechanism such as CpG island 
hypermethylation may have brought about such a down-regulation.  
CpG island hypermethylation is a fundamental mechanism for loss of 
function of tumour suppressor and DNA repair genes in several tumours. A 
growing number of genes such as GSTP1, p16INK4a, APC and many more have 
been reported to undergo CpG hypermethylation in HCCs (Zhang et al., 2005; Li 
et al., 2005), which indicates its potential role in hepatocarcinogenesis. We thus 
suspect CRH-BP to be a tumour suppressor gene. 
The CRH binding protein has been proposed to modulate some endocrine 
and central nervous system (CNS) effects of CRH by anatomically or temporally 
limiting the action of the peptide (Vale et al., 1997). CRH-BP levels were shown 
to be significantly lesser in patients with liver disease than in healthy men 
(Trainer et al., 1998) and these low levels may support its hepatic origin. By 
evaluating the presence of α-MSH, ACTH and β-endorphin 
immunohistochemically in benign and malignant melanocytic lesions (Nagahama 
et al., 1998), CRH has been associated with the induction of proopiomelanocortin 
(POMC) mRNA expression which correlates to tumour progression (Sato et al., 
2002). In a study recently done, 75% of metastatic melanoma cases tested positive 
for POMC staining and 66% of the cases were positive for CRH (Sato et al., 
2002). One can thus conclude that high levels of expression of CRH might result 
in higher expression of POMC, thus endowing melanoma cells with growth and 
metastatic ability. In addition, CRH is expressed in neoplasms of the skin, 
prostate, lung, stomach, liver, and thymus (Carey et al., 1984; Suda et al., 1984; 
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Rosen et al., 1992; Kimura et al., 1996; Roloff et al., 1998), where it is usually 
associated with malignant behaviour. One can thus postulate that the increased 
expression of CRH in these tumours may be a result of the down-regulation of 
CRH-BP.  
In vitro studies done found CRH to be a potent stimulator of endothelial 
cell migration, a critical component of the angiogenic process. The same group 
that performed an in vivo assay concluded that CRH via CRH receptor could also 
stimulate angiogenesis and tumour growth. (Arbiser et al., 1999). Angiogenesis is 
an important component of inflammation, critical for tissue repair (Folkman, 
1995; Jackson et al. 1997). It is promoted by CRH interaction with the 
endothelium to cause arterial vasodilation via a CRH receptor-dependent 
mechanism involving nitric oxide (Jain et al. 1997). The ability of CRH to 
promote angiogenesis coupled with its location at sites of inflammation raises the 
possibility that it may have a paracrine role in the link between inflammation and 
angiogenesis (Arabiser et al., 1999). Therefore, we can assume that the high 
concentration of free CRH has a correlation with the low concentration of CRH-
BP in tumours. 
CRH is also expressed in the immune system (Karalis et al., 1997). It is 
found in acute inflammatory states, including, cutaneous inflammation, 
inflammatory bowel disease and rheumatoid arthritis (Crofford et al., 1992; Scopa 
et al., 1994; Kawahito et al., 1995). 
The results presented in this paper indicate that DNA methylation plays an 
important role in the regulation of CRH-BP expression in human HCC cells. This 
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conclusion is based upon the following observations. Firstly, in contrast to tumour 
tissues, CRH-BP was expressed in much greater amounts in the corresponding 
paired normal tissue as confirmed by real-time PCR. Semi-quantitative RT-PCR 
failed to detect CRH-BP expression in all the 14 HCC cell lines tested but showed 
that the gene was expressed ubiquitously in all 15 normal tissue tested. Treatment 
of the 14 HCC cell lines with 5-Aza-dC results in simultaneous de novo synthesis 
of CRH-BP RNA for 11 out of the 14 cell lines. These results provide compelling 
evidence that methylation silences CRH-BP expression and that demethylation or 
hypomethylation permit transcriptional activation of the gene. MSP on the 
bisulphite treated DNA revealed that the 5’CpG island of CRH-BP was 
methylated in almost all 14 HCC cell lines except Huh4. In the primary HCC 
tissues, five of six cases showed CRH-BP hypermethylation. This suggests that 
there may be other mechanisms of gene silencing such as the presence of non-
coding RNA, histone modification or chromatin remodelling taking place. 
Together, this data suggests that CRH-BP is usually transcriptionally repressed 
mainly due to promoter hypermethylation. 
In conclusion, CRH-BP is known to be involved in modulating the 
bioactivity of circulating CRH and related ligands. It is thus imperative in 
regulating the stress response and bringing about the local tissue inflammatory 
responses in various diseases like rheumatoid arthritis. The role of CRH normally 
expressed in peripheral sites such as the immune system with its ability to 
enhance angiogenesis suggests the possibility that ectopic CRH production is not 
just a random event. As a regulator of free CRH, CRH-BP thus plays an indirect 
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role in tumourgenesis through either POMC activation, angiogenesis or some 
other undiscovered function. Since its concentration in the blood is higher than 
CRH, is may be a good gauge of the concentration of free CRH. CRH-BP can 
thus be used as a diagnostic marker for HCC and other cancers. As a regulator of 
CRH, there is also a great prospect of CRH-BP being a drug target in the future to 
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